论文部分内容阅读
目的 :探讨非小细胞肺癌组织端粒酶活性表达及其临床意义。方法 :应用TRAP -PCR -ELISA方法检测36例非小细胞肺癌组织及相应的 32例癌旁组织 ,9例肺良性病变组织和 9例正常肺组织中端粒酶活性表达。结果 :肺癌组织中端粒酶活性表达阳性率为 75 % (2 7/ 36 ) ,癌旁组织为 6 .2 5 % (2 / 32 ) ,肺良性病变组织为 11.1% (1/ 9) ,正常肺组织为 0 % (0 / 9)。肺癌组织端粒酶活性表达与肺癌病理类型、组织分化程度、原发肿瘤大小、淋巴结转移情况及临床分期无明显相关。结论 :端粒酶在肺癌组织中的高表达可作为肺癌诊断和鉴别诊断的重要分子生物学指标之一
Objective: To investigate the expression of telomerase activity in non-small cell lung cancer and its clinical significance. Methods : TRAP-PCR-ELISA was used to detect the expression of telomerase activity in 36 cases of non-small cell lung cancer and 32 cases of adjacent non-small cell lung cancer tissues, 9 cases of benign lung disease tissues and 9 cases of normal lung tissues. RESULTS: The positive rate of telomerase activity in lung cancer tissues was 75% (2 7/36), 6.25% (2/32) in adjacent tissues, and 11.1% (1/ 9) in benign lung tissues. Normal lung tissue was 0 % (0 / 9). There was no significant correlation between the expression of telomerase activity and the pathological type, histological grade, primary tumor size, lymph node metastasis and clinical stage of lung cancer. Conclusion: The high expression of telomerase in lung cancer can be used as one of the important molecular biological indicators for the diagnosis and differential diagnosis of lung cancer.